FDA approves Mounjaro and Zepbound KwikPen supplements after Lilly's December responses

Eli Lilly's December 2, 2025 amendments resolved two FDA action letters that had been holding up its KwikPen applications for Mounjaro and Zepbound, and the agency approved both supplements about seven weeks later, on January 20, 2026 ^[1][2].

The approvals cover Zepbound KwikPen under supplement NDA 217806/S-002 and Mounjaro KwikPen under supplement NDA 215866/S-009. Both products contain the active ingredient tirzepatide ^[1][2]. Each FDA letter states that the agency received "your amendment dated December 2, 2025, which constituted a complete response to our January 29, 2025, action letter" ^[1][2]. The letters do not describe what FDA's January 2025 questions were, and the agency had not approved the applications at that point.

Both supplements were filed well before that. The Zepbound KwikPen application was dated and received November 15, 2023, and the Mounjaro KwikPen application was dated and received September 28, 2023 ^[1][2]. Each asked FDA to revise the prescribing information and medication guide and to approve new carton and container labeling and instructions for use ^[1][2].

What the approvals add is a device format: six presentations of each KwikPen, each containing 4 doses of a fixed volume of tirzepatide for once-weekly administration ^[1][2]. The strength of each presentation is redacted in the letters, so the specific milligrams per dose are not stated in the approval documents.

Both letters direct one labeling change before the cartons are printed: revise "mg/dose" to "mg per dose" for clarity ^[1][2]. Both also state that the products are exempt from pediatric study requirements under the Pediatric Research Equity Act, on the grounds that the supplements do not involve a new active ingredient, a new indication, a new dosage form, a new dosing regimen or a new route of administration ^[1][2].

Why it matters for patients

Mounjaro and Zepbound are already sold in other formats. The approval letters list previously approved instructions for use for single-dose pens, single-dose vials and multi-dose vials, which remain part of the labeling ^[1][2]. Whether the KwikPen will replace those formats or be sold alongside them has not been reported.

A KwikPen holding four doses means fewer individual devices per month of therapy than a single-dose pen, but the letters do not discuss injection routine, storage, needle requirements or training. Those details would appear in the Instructions for Use and Medication Guide that FDA approved as part of these supplements; the approval letters do not reproduce their contents ^[1][2].

Several practical questions are unanswered in the approval documents. Neither letter states a price, an insurance coverage position, a copay program or a launch date. Neither letter says whether the KwikPen presentations will be available in the same strengths as current pens, because the strengths are redacted ^[1][2]. Whether supplies will be limited at launch has not been disclosed.

For anyone currently using a single-dose pen or a vial, nothing in these letters changes an existing prescription. The approvals add labeled presentations; they do not change the approved once-weekly dosing schedule described in the letters ^[1][2].

What happens next

Both letters set deadlines for Lilly, dated from the January 20, 2026 approval. Within 14 days, the company must submit the labeling content in structured product labeling format so it appears in public labeling repositories ^[1][2]. Final printed carton and container labeling, reflecting the "mg per dose" change, must be submitted no more than 30 days after it is printed; FDA approval of that submission is not required before the labeling is used ^[1][2]. Patent information for listing in the Orange Book must be filed on Form FDA 3542 within 30 days of approval ^[1][2].

No date for when KwikPens will reach pharmacies appears in either letter ^[1][2].